CompletedPhase 1

A Study of Itraconazole in Preventing the Return of Histoplasmosis, a Fungal Infection, in Patients With AIDS

United States30 participants

Plain-language summary

To test the effectiveness of itraconazole in preventing the recurrence of disseminated histoplasmosis in AIDS patients. Histoplasmosis is a serious opportunistic infection in patients with AIDS. Amphotericin B has been used to treat the infection. Although the response to this treatment is generally good, up to 90 percent of AIDS patients who have taken amphotericin B to treat their histoplasmosis infection will have a relapse (that is, they will get the disease again) within 12 months following treatment. Ketoconazole has been used to prevent relapse, but available information suggests that up to 50 percent of AIDS patients relapse even with ketoconazole treatment. A more effective therapy to prevent recurrence is needed. Itraconazole has been used successfully to treat disseminated histoplasmosis in non-AIDS patients and it is hoped that it may be more effective in preventing histoplasmosis relapse.

Who can participate

Age range13 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria Concurrent Medication: Itraconazole therapy must begin no more than 6 weeks after discontinuing primary amphotericin B therapy; itraconazole therapy may begin immediately after stopping the primary therapy with amphotericin B. Allowed: * Oral contraceptives. * Methadone. * Narcotics. * Acyclovir. * Acetaminophen. * Sulfonamides. * Trimethoprim / sulfamethoxazole. * Aerosolized pentamidine for Pneumocystis carinii pneumonia (PCP) or PCP prophylaxis (patients with a total CD4+ count \< 200 or a history of PCP should receive PCP prophylaxis). * Treatment IND drugs. * Zidovudine. * Topical antifungals. * Discouraged: * Antacids. * Sucralfate. * H2 blockers. Concurrent Treatment: Allowed: * Radiation therapy for mucocutaneous Kaposi's sarcoma. Prior Medication: Required: * Prior treatment with amphotericin B for disseminated histoplasmosis: * minimum total dose of 15 mg/kg for patients \< 67 kg, or 1 g for patients \> 67 kg; must have been administered over 6 months or less. Allowed: * Amphotericin B as maintenance therapy for a maximum of 6 weeks following completion of primary therapy. * Zidovudine. * Prophylaxis for Pneumocystis carinii pneumonia. Exclusion Criteria Co-existing Condition: Patients with the following conditions are excluded: * History of allergy to, or intolerance of, imidazoles or azoles. * Clinical findings of active histoplasmosis. * Histoplasmosis of the central nervous system. * Inability to take oral medications reliably …

Trial details

NCT IDNCT00000992

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)

Sponsor typeNIH

Study typeINTERVENTIONAL